261 related articles for article (PubMed ID: 11741249)
21. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population.
Dorado P; Heras N; Machín E; Hernández F; Teran E; Llerena A
Eur J Clin Pharmacol; 2012 May; 68(5):637-44. PubMed ID: 22083166
[TBL] [Abstract][Full Text] [Related]
22. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
24. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
25. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers.
Takashima T; Murase S; Iwasaki K; Shimada K
Drug Metab Pharmacokinet; 2005 Jun; 20(3):177-82. PubMed ID: 15988119
[TBL] [Abstract][Full Text] [Related]
28. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.
Gaedigk A; Gotschall RR; Forbes NS; Simon SD; Kearns GL; Leeder JS
Pharmacogenetics; 1999 Dec; 9(6):669-82. PubMed ID: 10634130
[TBL] [Abstract][Full Text] [Related]
29. [Distinguishing CYP2D6 homozygous and heterozygous extensive metabolizers by dextromethorphan phenotyping].
Chen SQ; Cai WM; Wedlund PJ
Yao Xue Xue Bao; 1997 Dec; 32(12):924-7. PubMed ID: 11596190
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
31. Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.
Dorado P; González I; Naranjo ME; de Andrés F; Peñas-Lledó EM; Calzadilla LR; LLerena A
OMICS; 2017 Jan; 21(1):17-26. PubMed ID: 28271978
[TBL] [Abstract][Full Text] [Related]
32. The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer.
Trojan A; Vergopoulos A; Breitenstein U; Seifert B; Rageth C; Joechle W
Breast Care (Basel); 2012 Feb; 7(1):25-31. PubMed ID: 22553469
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction.
Monte AA; West K; McDaniel KT; Flaten HK; Saben J; Shelton S; Abdelmawla F; Bushman LR; Williamson K; Abbott D; Anderson PL
Clin Pharmacol Ther; 2018 Nov; 104(5):933-939. PubMed ID: 29882961
[TBL] [Abstract][Full Text] [Related]
34. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening.
Wieling J; Tamminga WJ; Sakiman EP; Oosterhuis B; Wemer J; Jonkman JH
Ther Drug Monit; 2000 Aug; 22(4):486-96. PubMed ID: 10942192
[TBL] [Abstract][Full Text] [Related]
36. [Correlation of genetic polymorphism of cytochrome P4502D6 with dextromethorphan oxidative metabolism in Chinese].
Cai W; Chen B; Tao X; Ling S; Zhang Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Jun; 17(3):181-4. PubMed ID: 10837520
[TBL] [Abstract][Full Text] [Related]
37. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
38. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML
Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915
[TBL] [Abstract][Full Text] [Related]
39. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
40. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.
Basci NE; Bozkurt A; Kayaalp SO; Sayal A; Isimer A
Eur J Drug Metab Pharmacokinet; 1998; 23(1):1-5. PubMed ID: 9625265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]